Use of the bacterial lysate OM-85 for the primary prevention of wheezing lower respiratory illness in preschool children: a randomised, placebo-controlled trial
Source: View publication →
In a randomized trial of high-risk preschool children, prophylactic oral administration of the bacterial lysate OM-85 for 24 months did not significantly reduce the time to first wheezing lower respiratory tract illness during a subsequent 36-month off-drug observation period.
Key Findings
Study Design
Study Limitations
Clinical Significance
This trial robustly demonstrates that early-life administration of the bacterial lysate OM-85 does not alter the underlying disease trajectory or prevent asthma-like symptoms in high-risk infants, discouraging its clinical use for the primary prevention of wheezing lower respiratory tract illnesses.
Historical Context
Recurrent wheezing in preschool children is a major driver of pediatric healthcare utilization and a precursor to asthma. Inspired by the 'hygiene hypothesis,' researchers have extensively investigated whether early-life immunomodulation via microbial exposure can prevent allergic diseases. While earlier, smaller studies suggested bacterial extracts like OM-85 might reduce the frequency of acute respiratory infections, the ORBEX trial rigorously tested the long-term, disease-modifying potential of OM-85 for the primary prevention of wheezing. Its negative results cast significant doubt on the viability of this pathway for asthma prevention.
Guided Discussion
High-yield insights from every perspective
What is the proposed immunologic mechanism by which a bacterial lysate like OM-85 was originally theorized to prevent recurrent wheezing or asthma development in preschool children?
Key Response
This tests foundational immunology and the hygiene hypothesis. Bacterial lysates were theorized to stimulate innate immune receptors (like Toll-like receptors) on mucosal surfaces, promoting a shift from a Th2 (allergic/asthma) phenotype toward a Th1 and regulatory T-cell response, thereby theoretically reducing atopic sensitization and subsequent viral-induced wheezing.
Given the negative findings of this trial, how should you counsel parents of a high-risk preschooler with recurrent wheezing who ask about using prescription or over-the-counter immunostimulants to prevent asthma?
Key Response
Residents must translate trial data into practical patient counseling. The rationale is to definitively advise against the use of OM-85 for primary prevention due to a lack of long-term efficacy, and instead pivot the conversation to guideline-directed therapies such as PRN or daily inhaled corticosteroids (ICS) or leukotriene receptor antagonists for those with frequent symptoms.
The trial specifically evaluated a 36-month off-drug observation period after 24 months of therapy to assess primary prevention. Why is distinguishing between primary disease modification and secondary exacerbation reduction critical when evaluating therapies in the heterogeneous population of preschool wheezers?
Key Response
Fellows must understand disease phenotyping and trial endpoints. Preschool wheeze is highly heterogeneous (transient viral wheeze vs. multiple-trigger atopic asthma). An intervention might temporarily reduce viral infections (secondary prevention) while actively on-drug, but failing to delay the time to first wheeze off-drug indicates it does not fundamentally alter the underlying immune trajectory or natural history of the child's disease.
OM-85 has been prescribed in various global regions for decades based on early, less rigorous data and biological plausibility. How does this large, negative, long-term RCT impact our approach to de-adopting legacy therapies in pediatric pulmonology?
Key Response
This highlights the challenge of de-implementation in clinical practice. The rationale focuses on teaching trainees to demand high-quality, long-term RCTs for disease-modifying claims, and recognizing the importance of stopping ineffective, low-value care even if the intervention is perceived as safe or mechanistically sound.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
In a 5-year longitudinal trial (2 years on-drug, 3 years off-drug) assessing time to first wheezing lower respiratory illness, how might interval censoring and informative dropout threaten the validity of the Kaplan-Meier estimates and Cox proportional hazards models used?
Key Response
This focuses on the statistical methodology of long-term pediatric trials. Dropout rates over 5 years are often high. If children drop out because they develop severe symptoms and seek outside treatments, or conversely because they are entirely healthy and parents lose interest, the censoring is informative. This violates the fundamental assumption of survival analysis and potentially biases the hazard ratio.
As a peer reviewer evaluating this manuscript, what critical data regarding medication adherence during the 24-month prophylactic phase and the specific phenotypic definition of the high-risk cohort would you scrutinize to ensure the null result is a true lack of efficacy rather than a type II error?
Key Response
Reviewers must look for methodological flaws that cause false negatives. Poor adherence over a 2-year daily regimen naturally biases results toward the null. Furthermore, if the high-risk inclusion criteria were too broad, including many children destined to outgrow transient wheeze regardless of intervention, it would severely dilute any potential preventative signal.
Based on this definitive lack of long-term efficacy, how should organizations like GINA (Global Initiative for Asthma) update their recommendations regarding the use of bacterial lysates for the primary prevention of preschool wheezing?
Key Response
Current GINA guidelines note that while some earlier studies suggested bacterial lysates might reduce viral respiratory infections, their routine use is not recommended for asthma management. This study provides robust, high-level evidence to strengthen that stance to a strong, formal recommendation against the use of OM-85 for the primary prevention of wheezing illnesses in high-risk preschoolers, directing clinical focus back to proven therapies.
Clinical Landscape
Noteworthy Related Trials
PEAK Trial
Tested
Inhaled fluticasone propionate
Population
Preschoolers at high risk for asthma
Comparator
Placebo
Endpoint
Proportion of episode-free days
Razi OM-85 Trial
Tested
OM-85 bacterial lysate
Population
Children aged 1 to 6 years with recurrent wheezing
Comparator
Placebo
Endpoint
Number and duration of wheezing attacks
APRIL Trial
Tested
Azithromycin
Population
Children 12 to 71 months with recurrent severe LRTI
Comparator
Placebo
Endpoint
Progression to severe lower respiratory tract illness
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis